PHC signs second Innatus 3G deal
The US-based, UK-listed bioproducts company, Plant Health Care (PHC - Raleigh, North Carolina), has signed an agreement with a second unnamed "major industry player" to evaluate its Innatus 3G peptide platform. It allows the design, production and screening of a large pipeline of peptides with diverse biostimulant properties, PHC notes. They can be used for seed treatment and foliar applications for boosting disease resistance, drought tolerance and yield. PHC signed a similar deal in April. "Our goal was to sign at least two evaluation agreements for our Innatus 3G peptide platform this year and we have accomplished that within the first five months," says PHC's chief executive officer, Paul Schmidt. "We are targeting the largest players and these agreements reflect the potential value they see in our platform. Our dialogue with the other major players is ongoing."